Suppr超能文献

从多个配体复合物结构深入了解布鲁顿酪氨酸激酶的构象灵活性。

Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures.

机构信息

Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, California 94304, USA.

出版信息

Protein Sci. 2011 Feb;20(2):428-36. doi: 10.1002/pro.575.

Abstract

Bruton's tyrosine kinase (BTK) plays a key role in B cell receptor signaling and is considered a promising drug target for lymphoma and inflammatory diseases. We have determined the X-ray crystal structures of BTK kinase domain in complex with six inhibitors from distinct chemical classes. Five different BTK protein conformations are stabilized by the bound inhibitors, providing insights into the structural flexibility of the Gly-rich loop, helix C, the DFG sequence, and activation loop. The conformational changes occur independent of activation loop phosphorylation and do not correlate with the structurally unchanged WEI motif in the Src homology 2-kinase domain linker. Two novel activation loop conformations and an atypical DFG conformation are observed representing unique inactive states of BTK. Two regions within the activation loop are shown to structurally transform between 3(10)- and α-helices, one of which collapses into the adenosine-5'-triphosphate binding pocket. The first crystal structure of a Tec kinase family member in the pharmacologically important DFG-out conformation and bound to a type II kinase inhibitor is described. The different protein conformations observed provide insights into the structural flexibility of BTK, the molecular basis of its regulation, and the structure-based design of specific inhibitors.

摘要

布鲁顿酪氨酸激酶(BTK)在 B 细胞受体信号转导中发挥关键作用,被认为是淋巴瘤和炎症性疾病有前途的药物靶点。我们已经确定了 BTK 激酶结构域与来自不同化学类别的六种抑制剂复合物的 X 射线晶体结构。五种不同的 BTK 蛋白构象通过结合抑制剂得到稳定,为 Gly-丰富环、螺旋 C、DFG 序列和激活环的结构灵活性提供了见解。构象变化独立于激活环磷酸化发生,与Src 同源 2 激酶结构域接头中结构不变的 WEI 基序无关。观察到两种新型激活环构象和一种非典型 DFG 构象,代表 BTK 的独特非活性状态。激活环内的两个区域被证明在 3(10)-和α-螺旋之间结构转化,其中一个折叠到腺苷-5'-三磷酸结合口袋中。描述了第一个处于药理学上重要的 DFG-out 构象的 Tec 激酶家族成员的晶体结构,并与 II 型激酶抑制剂结合。观察到的不同蛋白质构象为 BTK 的结构灵活性、其调节的分子基础以及基于结构的特异性抑制剂设计提供了见解。

相似文献

5
Bruton's TK inhibitors: structural insights and evolution of clinical candidates.
Future Med Chem. 2014 Apr;6(6):675-95. doi: 10.4155/fmc.14.24.
7
X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinase.
Chem Biol Drug Des. 2011 Nov;78(5):739-48. doi: 10.1111/j.1747-0285.2011.01230.x. Epub 2011 Sep 21.
9
Solution structure of the human BTK SH3 domain complexed with a proline-rich peptide from p120cbl.
J Biomol NMR. 2000 Apr;16(4):303-12. doi: 10.1023/a:1008376624863.
10
Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.
Int J Mol Sci. 2020 Dec 4;21(23):9269. doi: 10.3390/ijms21239269.

引用本文的文献

2
Design, synthesis and evaluation of a series of potential prodrugs of a Bruton's tyrosine kinase (BTK) inhibitor.
Front Pharmacol. 2023 Mar 8;14:1162216. doi: 10.3389/fphar.2023.1162216. eCollection 2023.
4
Reactivities of the Front Pocket N-Terminal Cap Cysteines in Human Kinases.
J Med Chem. 2022 Jan 27;65(2):1525-1535. doi: 10.1021/acs.jmedchem.1c01186. Epub 2021 Oct 14.
5
Disrupting enzyme fluidity.
Elife. 2021 Jan 25;10:e65221. doi: 10.7554/eLife.65221.
8
Discovery and Evaluation of Pyrazolo[3,4-]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor.
ACS Med Chem Lett. 2019 Dec 11;11(10):1863-1868. doi: 10.1021/acsmedchemlett.9b00395. eCollection 2020 Oct 8.
9
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk mutation in B-cell malignancies.
Br J Pharmacol. 2019 Dec;176(23):4491-4509. doi: 10.1111/bph.14809. Epub 2019 Dec 9.

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
2
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
N Engl J Med. 2010 Sep 30;363(14):1303-12. doi: 10.1056/NEJMoa1000500. Epub 2010 Sep 22.
3
Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
Expert Opin Ther Pat. 2010 Nov;20(11):1457-70. doi: 10.1517/13543776.2010.517750. Epub 2010 Sep 10.
4
Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation.
Chem Biol Drug Des. 2010 Aug;76(2):154-63. doi: 10.1111/j.1747-0285.2010.00993.x. Epub 2010 Jun 9.
7
A novel Syk kinase inhibitor suitable for inhalation: R-343(?)--WO-2009031011.
Expert Opin Ther Pat. 2009 Oct;19(10):1469-72. doi: 10.1517/13543770903059281.
8
Bruton's tyrosine kinase as a drug discovery target.
Drug News Perspect. 2008 Sep;21(7):357-62. doi: 10.1358/dnp.2008.21.7.1255308.
9
Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes.
Chem Biol Drug Des. 2009 Apr;73(4):466-70. doi: 10.1111/j.1747-0285.2009.00785.x. Epub 2009 Feb 7.
10
Structural biology contributions to tyrosine kinase drug discovery.
Curr Opin Cell Biol. 2009 Apr;21(2):280-7. doi: 10.1016/j.ceb.2009.01.012. Epub 2009 Feb 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验